Issa Kildani is the Managing Partner and Founder of Ambrosia Ventures, a boutique strategic consulting and M&A advisory firm operating at the intersection of life sciences, compliance, and capital efficiency. His firm partners with biotech, pharma, medtech, and digital health leaders to de-risk decisions from strategy through value capture, spanning market intelligence, business model innovation, regulatory and quality remediation, commercial readiness, disciplined buy-/sell-side execution, and post-merger growth. Issa’s transaction experience includes advising transactions $1.0B+ in acquisition deals and advising Fortune-scale healthcare organizations, and PE-backed platforms on integration, synergy realization, and risk governance. On the front end, he builds evidence-weighted market maps and commercial diligence that pressure-test assumptions before capital is deployed. A builder as well as an operator, Issa created AlaricAI, an investment discovery and diligence platform trained on 100,000+ companies and 160M+ signals. AlaricAI surfaces defensible targets, scores relevance and performance, and generates investor-grade dashboards, compressing weeks of research into hours while preserving auditability and compliance trails. Issa is advancing an operator-investor thesis focused on AI-accelerated diligence, compliance-by-design, and value creation in regulated markets with a clear bias toward measurable inflection milestones and capital discipline. As the New York Chapter Director for VNTR, he convenes invite-only roundtables that put institutional LPs, family offices, strategics, and founders in the same room to align on theses. A frequent speaker and moderator, Issa is known for a pragmatic, risk-first point of view on AI in drug development, the buy-side shift toward earlier-stage assets, and the operational realities of global regulatory harmonization. He holds a B.A. in Psychology from Wayne State University and an M.S. in Biomedical Science from Grand Valley University.